Clinical trials
Higher-risk Myelodysplastic Syndrome clinical trials
Below are recruiting higher-risk myelodysplastic syndrome clinical trials, each written for real people, not researchers. We’re tracking 17 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Berkeley, CaliforniaAges 18 years+ - NCT06196203RecruitingPhase 2
Study of AK117 with Azacitidine for High-Risk MDS
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT07047183RecruitingPhase 2
A study of venetoclax and azacitidine before stem cell transplant for MDS
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
Changchun, JilinAges 18 years+ - NCT06471946RecruitingPhase 1/Phase 2
Stem cell transplant for older patients with high-risk MDS
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06641414RecruitingPhase 3
Lisaftoclax and azacytidine for higher-risk MDS
This trial tests a new drug, lisaftoclax, combined with azacytidine for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this combination can help control the disease better.
Houston, TexasAges 18 years+ - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT05365035RecruitingPhase 2
Phase 2 trial for high-risk blood cancers with timed chemo
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Houston, TexasAges 18 years+ - NCT06297941RecruitingPhase 1
Study of REM-422 for AML or high-risk MDS
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT06918834RecruitingPhase 2
Immediate vs bridging transplant for high-risk MDS
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
Beijin, Beijing MunicipalityAges 18 years+ - NCT07155226RecruitingPhase 1/Phase 2
Study of AZD3632 for advanced blood cancers with certain gene changes
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
Decatur, IllinoisAges 16 years+ - NCT07283900RecruitingPhase 2
Vitamin C with chemotherapy for higher-risk MDS
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
Iowa City, IowaAges 18–99 - NCT07761533RecruitingPhase 1/Phase 2
PBSS1113 plus azacitidine for blood cancers
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT03999723RecruitingPhase 2
Test azacitidine with vitamin C to improve DNA changes
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
AalborgAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Higher-risk Myelodysplastic Syndrome trials by city
Studies with a site in or near these metro areas.
Higher-risk Myelodysplastic Syndrome trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for higher-risk myelodysplastic syndrome?
- Yes. Clin2 currently lists 17 recruiting higher-risk myelodysplastic syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a higher-risk myelodysplastic syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a higher-risk myelodysplastic syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.